Enzyme Replacement Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2028

 

Enzyme replacement therapy involves the intravenous administration of enzymes in order to correct the enzyme deficiency that causes lysosomal storage disease. In Fabry disease, Gaucher disease, lysosomal acid lipase deficiency, mucopolysaccharidosis, Hunter syndrome, and Pompe disease, enzyme replacement therapy is used. Enzymes are derived from human cells, animal cells, and recombinant DNA technology. Although Enzyme Replacement Therapy Market does not provide a permanent cure, it does help to prevent permanent damage to the body caused by a lack of a specific enzyme. Depending on the disease, treatment consists of weekly or monthly doses. To address enzyme deficiency in Gaucher disease, for example, a modified version of glucocerebrosidase is administered intravenously every two weeks.

Enzyme Replacement Therapy Market is used to replace a missing or deficient enzyme in a person with an inherited enzyme deficiency syndrome. It replenishes the patient's body's deficient enzymes either intravenously (IV) or orally. People prefer the IV route, in which the replacement enzyme is delivered directly into the bloodstream via a controlled drip of fluids.

Infusions of an enzyme purified from human or animal tissue or blood or produced using novel recombinant DNA techniques replace the missing enzyme. The enzyme is modified to have a longer half-life, greater activity, and resistance to degradation.

Enzyme Replacement Therapy Market In a person with an inherited enzyme deficiency syndrome, market is used to replace a missing or deficient enzyme. It either intravenously (IV) or orally replenish the patient's body's deficient enzymes. The IV route is preferred because the replacement enzyme is delivered directly into the bloodstream via a controlled drip of fluids.

The missing enzyme is replaced by infusions of an enzyme purified from human or animal tissue or blood or produced using novel recombinant DNA techniques. The enzyme has been altered to have a longer half-life, higher activity, and resistance to degradation.

Key Players

Shire plc, Amicus Therapeutics, Genzyme Corporation, Pfizer Inc., BioMarin Pharmaceutical, Inc., Sigma-Tau Pharmaceuticals, Inc., Essential Pharmaceuticals Limited, Merck KGa, and AbbVie Inc. are key players in the global enzyme replacement therapy market.

x